These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 23628483)
1. Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time. Sandmann FG; Franken MG; Steenhoek A; Koopmanschap MA Health Policy; 2013 Oct; 112(3):285-96. PubMed ID: 23628483 [TBL] [Abstract][Full Text] [Related]
2. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement]. Hoomans T; van der Roer N; Severens JL; Delwel GO Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045 [TBL] [Abstract][Full Text] [Related]
3. Unravelling drug reimbursement outcomes: a comparative study of the role of pharmacoeconomic evidence in Dutch and Swedish reimbursement decision making. Franken M; Nilsson F; Sandmann F; de Boer A; Koopmanschap M Pharmacoeconomics; 2013 Sep; 31(9):781-97. PubMed ID: 23839699 [TBL] [Abstract][Full Text] [Related]
4. Methodological quality of economic evaluations of new pharmaceuticals in The Netherlands. Hoomans T; Severens JL; van der Roer N; Delwel GO Pharmacoeconomics; 2012 Mar; 30(3):219-27. PubMed ID: 22074610 [TBL] [Abstract][Full Text] [Related]
5. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond. Rocchi A; Menon D; Verma S; Miller E Value Health; 2008; 11(4):771-83. PubMed ID: 18179658 [TBL] [Abstract][Full Text] [Related]
6. Health economic evaluations in reimbursement decision making in the Netherlands: time to take it seriously? Franken M; Koopmanschap M; Steenhoek A Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):383-9. PubMed ID: 25444296 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial. Majer IM; Gelderblom H; van den Hout WB; Gray E; Verheggen BG J Med Econ; 2013 Sep; 16(9):1106-19. PubMed ID: 23808902 [TBL] [Abstract][Full Text] [Related]
8. Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests. Cleemput I; van Wilder P; Huybrechts M; Vrijens F Value Health; 2009 Jun; 12(4):441-9. PubMed ID: 19900251 [TBL] [Abstract][Full Text] [Related]
9. The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada. Yong JH; Beca J; Hoch JS Pharmacoeconomics; 2013 Mar; 31(3):229-36. PubMed ID: 23322588 [TBL] [Abstract][Full Text] [Related]
10. Drug reimbursement decision-making in Thailand, China, and South Korea. Ngorsuraches S; Meng W; Kim BY; Kulsomboon V Value Health; 2012; 15(1 Suppl):S120-5. PubMed ID: 22265058 [TBL] [Abstract][Full Text] [Related]
11. A synthesis of drug reimbursement decision-making processes in organisation for economic co-operation and development countries. Barnieh L; Manns B; Harris A; Blom M; Donaldson C; Klarenbach S; Husereau D; Lorenzetti D; Clement F Value Health; 2014; 17(1):98-108. PubMed ID: 24438723 [TBL] [Abstract][Full Text] [Related]
12. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria]. Führlinger S Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765 [TBL] [Abstract][Full Text] [Related]
13. Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib? Franken MG; Gaultney JG; Blommestein HM; Huijgens PC; Sonneveld P; Redekop WK; Uyl-de Groot CA Value Health; 2014 Mar; 17(2):245-53. PubMed ID: 24636383 [TBL] [Abstract][Full Text] [Related]
14. Similarities and differences between five European drug reimbursement systems. Franken M; le Polain M; Cleemput I; Koopmanschap M Int J Technol Assess Health Care; 2012 Oct; 28(4):349-57. PubMed ID: 22989410 [TBL] [Abstract][Full Text] [Related]
15. [Pharmaco-economic evaluations of new drugs: potential key to a more efficient allocation of the health care budget]. Delwel GO; Sprenger MJ Ned Tijdschr Geneeskd; 2002 Jun; 146(23):1068-71. PubMed ID: 12085554 [TBL] [Abstract][Full Text] [Related]
16. Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013. Pauwels K; Huys I; De Nys K; Casteels M; Simoens S Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):859-68. PubMed ID: 25978862 [TBL] [Abstract][Full Text] [Related]
17. Reimbursement of targeted cancer therapies within 3 different European health care systems. Mihajlović J; Dolk C; Tolley K; Simoens S; Postma MJ Clin Ther; 2015 Feb; 37(2):474-80. PubMed ID: 25638534 [TBL] [Abstract][Full Text] [Related]
18. Balancing early access with uncertainties in evidence for drugs authorized by prospective case series - systematic review of reimbursement decisions. Wallerstedt SM; Henriksson M Br J Clin Pharmacol; 2018 Jun; 84(6):1146-1155. PubMed ID: 29381234 [TBL] [Abstract][Full Text] [Related]
19. Twenty years of using economic evaluations for drug reimbursement decisions: what has been achieved? Drummond M J Health Polit Policy Law; 2013 Dec; 38(6):1081-102. PubMed ID: 23974475 [TBL] [Abstract][Full Text] [Related]
20. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. Dusetzina SB; Winn AN; Abel GA; Huskamp HA; Keating NL J Clin Oncol; 2014 Feb; 32(4):306-11. PubMed ID: 24366936 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]